Endocrine effects of the podophyllotoxine derivative drug CPH 82 (Reumacon®) in patients with rheumatoid arthritis

By Carlström Kjell   Hedin Per-Johan   Jönsson Lennart   Lerndal Thomas   Lien Jon   Weitoft Tomas   Axelson Magnus  

Scandinavian Journal of Rheumatology, Vol. 29, Iss. 2, 2000-05 ,pp. : 89-94

Informa Healthcare

Access to resources Recommend Favorite

Glucocorticoid-like anti-inflammatory versus immunosuppressive effects of CPH 82 as a single drug therapy of moderately active rheumatoid arthritis patients: EDITORIAL COMMENT

By Masi Alfonse   Chatterton Robert  

Scandinavian Journal of Rheumatology, Vol. 29, Iss. 2, 2000-05 ,pp. : 85-88

Informa Healthcare

Access to resources Recommend Favorite

Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression

By Nishina Naoshi   Kaneko Yuko   Kameda Hideto   Kuwana Masataka   Takeuchi Tsutomu  

Clinical Rheumatology, Vol. 32, Iss. 11, 2013-11 ,pp. : 1661-1666

Springer Publishing Company

Access to resources Recommend Favorite

CPH-82 (Reumacon®) versus auranofin (ridaura®): A 36-week study of their respective onset of action rates in RA

By Bjørneboe O.   Moen F.   Nygaard H.   Haavik T. K.   Svensson B.  

Scandinavian Journal of Rheumatology, Vol. 27, Iss. 1, 1998-05 ,pp. : 26-31

Informa Healthcare

Access to resources Recommend Favorite

Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study

By Ateş Aşkin   Kinikli Gülay   Turgay Murat   Akay Gülay   Tokgöz Güner  

Clinical Rheumatology, Vol. 26, Iss. 4, 2007-04 ,pp. : 538-545

Springer Publishing Company

Access to resources Recommend Favorite